Novo Nordisk is committed to driving change for people with, or at risk of, cardiovascular disease
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. For almost 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems.
At Novo Nordisk, we are working to drive change to defeat diabetes and other serious chronic diseases, including cardiovascular disease. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease.
We are well positioned to make a significant difference in the lives of people living with cardiovascular diseases. We have established evidence of cardiovascular risk reduction from our existing GLP-1 RA portfolio in people living with type 2 diabetes and established cardiovascular disease and we are exploring this further with our ongoing trials. We also have a strong pipeline of cardiovascular assets spanning phase 1–3 clinical trials, targeting both atherosclerotic cardiovascular disease and heart failure.
8 January 2025
18:00
CET
Europe/ParisObesity: epidemiology, diagnosis, and impact on cardiovascular riskAccess event page https://esc365.escardio.org/event/16982025-01-08T18:00:002025-01-08T19:00:00
Register to Access
Obesity: epidemiology, diagnosis, and impact on cardiovascular risk
22 January 2025
18:00
CET
Europe/ParisObesity management: implications for cardiovascular risk reductionAccess event page https://esc365.escardio.org/event/16972025-01-22T18:00:002025-01-22T19:00:00
Register to Access
Obesity management: implications for cardiovascular risk reduction
/f/125658/1920x1080/d740d50967/webinar1-vignette.png)
/f/125658/1920x1080/149c71d71e/webinar2-vignette.png)
